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ABSTRACT
Introduction: Inflammation is an established
component of cardiovascular disease (CVD) and
an underlying factor of several dermatologic
conditions including rosacea, atopic dermatitis,
and psoriasis. Identifying potential associations
between these dermatologic and cardiovascular
diseases can better inform holistic healthcare
approaches. The objective of this study was to
determine whether rosacea, psoriasis or atopic
dermatitis are independent risk factors for CVD
1 year following diagnosis.
Methods: Using a large commercial claims
database of 21,801,147 lives, we employed a
propensity-matched logistic regression to
evaluate the association between diagnoses of
rosacea, psoriasis, or atopic dermatitis and a
1-year risk of being diagnosed with
cardiovascular disease. Control patients were
matched based on health-care utilization, age
and overall health status as defined by a
modified Deyo–Charlson comorbidity index.
Results: The analysis included 2105 rosacea,
622 atopic dermatitis, 1536 psoriasis, and 4263
control patients. Compared to
propensity-matched controls, the adjusted
odds of cardiovascular disease were not higher
in patients with rosacea (odds ratio: 0.894,
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p = 0.2713), atopic dermatitis (OR 1.032,
p = 0.8489), or psoriasis (OR 1.087,
p = 0.4210). In univariate analysis, the
unadjusted odds of cardiovascular disease was
higher in patients with psoriasis (OR 1.223,
p = 0.0347).
Conclusions: Limitations of this study include
the short follow-up period and inclusion of only
commercially insured patients limit the
generalizability of these findings. In this large
study of patients with rosacea, atopic
dermatitis, and psoriasis, we did not detect an
increased 1-year risk of cardiovascular disease
after adjusting for confounders.
Keywords: Atopic dermatitis; Cardiac health;
Eczema; Heart failure; Ischemic stroke;
Myocardial infarction; Psoriasis; Rosacea
INTRODUCTION
Most dermatologic conditions are readily
apparent to the physician taking care of the
patient and can be indicators of inflammatory
processes (i.e. atherosclerosis) occurring
internally. Some authors discuss an association
between psoriasis and cardiovascular disease
(CVD) [1–6]. Less clear associations exist
between other dermatologic inflammatory
conditions [atopic dermatitis (AD) and rosacea]
and CVD. Similar to psoriasis, these conditions
are (1) common and (2) may reflect underlying
systemic inflammation. Following this same
concept, these diseases are worth assessing for
their independent contribution to CVD risk.
Adults diagnosed with or self-identifying to
have AD are more likely to have risk factors
associated with CVD including: being a current
smoker (adjusted odds ratio (OR) 1.28,
p\0.001), being a current heavy drinker (OR
1.58, p\0.001), having a lifetime prevalence of
diabetes (OR 1.37, p\0.001), having a lifetime
prevalence of high cholesterol (OR 1.29,
p\0.001), or a lifetime prevalence of
hypertension (OR 1.31, p\0.001) [7]. Using a
Taiwanese nationwide database, a retrospective
population-based study identified 20,323
patients with AD and 20,323
comorbidity-matched subjects (age C20 years).
After adjusting for age, sex, comorbidities, and
medications used, the hazard ratio for
experiencing ischemic stroke over a 4-year
follow-up period was 1.33 (p = 0.001),
suggesting AD may be an independent risk
factor of ischemic stroke [8].
For rosacea, a case control study done by
Duman et al. assessed the compared CVD risk
factors for 60 rosacea patients and 50 age- and
gender-matched controls. Rosacea patients were
more likely than controls to have: high total
cholesterol (199 mg/dL vs. 163, p\0.001), LDL
(121 vs 101, p = 0.002), CRP levels (0.43 vs.
0.24 mg/L, p = 0.007), and a family history of
premature CVD (p = 0.002) [9]. This study only
assessed risk factors and did not look at
cardiovascular endpoints. Also, the control
subjects were only age and gender matched, so
invariably there was residual confounding.
Nevertheless, patients with rosacea may be
more likely to have CVD risk factors but this
has not been shown to be an independent risk
factor for CVD.
In this study, we evaluate whether three
dermatologic diseases that have inflammatory
components contribute an independent risk for
development of CVD outcomes at 1-year
follow-up using a large commercial claims
database.
METHODS
The data were analyzed as a case–control study
with matching on covariates using propensity
scores to quantify the association between the
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dermatologic diseases and CVD outcomes. The
matching done with propensity scores used a
Mahalanobis 1:1 algorithm using all the main
effects from the regression except the
dermatologic disease indicator variable [9].
Setting and Participants
All variables come from the MarketScanTM
Commercial Claims and Encounters database
for 2005–2007 [10]. No new studies with human
or animal subjects were performed by any of the
authors. The people included in the analysis
were in the range of 30–64 years old and had at
least 1 year of follow-up data and 6 months of
baseline data. We chose the lower age limit
because CVD is less common in individuals
younger than this age. We chose the upper age
limit to minimize loss to follow-up that could
occur from 65 year olds switching from
commercial insurance to Medicare.
The dermatologic diseases group was
composed of three arms: rosacea (ICD-9
695.3), psoriasis (ICD-9 696.1), or AD (ICD-9
691.XX, except for 691.0X). None of the arms
have people with any of the other two skin
conditions. They were all defined with
diagnosis codes, having at least 2 entries each.
The dermatologic disease group was selected
further using a washout period. We defined our
washout period as at least a 180-day period after
a person’s first diagnosis on record since the
beginning of 2005 during which they received
no treatment for their skin condition.
Treatments identified during this washout
period included biologics, systemic treatments
(e.g., methotrexate and cyclosporine), vitamin
D analogs, calcineurin inhibitors, topical
corticosteroids, anthralin, coal tar, retinoids,
and ammonium lactate for psoriasis;
systemic treatments, antihistamines (oral and
topical), calcineurin inhibitors, topical
corticosteroids ± anti-itching or anti-fungal/
bacterial agents, and anti-itch treatments (such
as calamine lotion) for AD); and oral antibiotics,
metronidazole, isotretinoin, retinoids, azelic
acid, benzoyl peroxide, calcineurin inhibitors,
sulfacetamide products, permethrin and
oxymetazoline. This method allowed for
creating a homogeneous set of recently
diagnosed people with medication
prescriptions for their illness.
The control group was comprised of people
selected with a simple random sample from the
database. None of the people in the control
group had any of the three skin diseases. In
order to match to the 1-year follow-up period
for the dermatologic disease group, the control
group was required to have complete data for
the whole of 2006.
The cases of cardiovascular disease were
defined as having at least 2 diagnosis codes
(ICD 9-CM) or at least one diagnosis code plus a
procedure code (CPT) for the disease.
Variables and Quantitative variables
We examined several covariates for explanation
of variance in the outcome and for their
intrinsic interest. Potential confounders
included age and gender, number of inpatient
days, number of days for which people had
outpatient visits, and total health-care
utilization costs. Since diabetes is a large risk
factor for CVD, we included it as a predictor of
CVD, defined by having at least 2 diagnosis
codes between 2005 and 2007. Overall
comorbid disease severity was examined with
the Deyo–Charlson Comorbidity Index with the
components related to the outcome removed.
Those components were CVD, peripheral
vascular disease (PVD), and old myocardial
infarction (MI). We also examined the number
of comorbid conditions, which could be as high
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as 14 (as opposed to the 17 conditions usually
examined with Deyo–Charlson). In addition to
the number of days spent in the hospital, we
examined the total number of hospitalizations
for the year but did not include this in the
regression in order to reduce multi-collinearity.
We also looked at the medication costs directly
related to the skin conditions as defined in the
washout period, for a total of 365 days
post-treatment. In addition to summing the
costs per person, we looked at the number of
prescription drug refills related to these costs for
that year. We further examined the total
medical costs divided into yearly inpatient,
outpatient, and medication costs.
Study Size
The sample size was determined by the
exclusion criteria and the eventual propensity
score selection. The control group originally
was comprised of 20,000 people and many were
not included because they did not match well to
the dermatologic disease group. Given the large
sample size, we did not perform a power
analysis prior to the study to estimate the
effect size we could detect.
Statistical Methods
The study was designed to examine the
independent risk of CVD among the
dermatologic conditions compared with a
general population of people in a commercial
insurance database. Cardiovascular disease
outcomes included ischemic heart disease
(ICD-9: 410–414), transient cerebral ischemia
(ICD-9: 435), heart failure (ICD-9: 428),
occlusion and stenosis of pre-cerebral arteries
(ICD-9: 433), and occlusion of cerebral arteries
(ICD-9: 434). Cases were required to have two
diagnosis codes or a diagnosis code plus a
cardiovascular-related procedure code
(Supplementary Table 1). We used a 365-day
follow-up period for the exposure and control
in order to standardize the results. Thus,
variables such as cost and healthcare
utilization will also be generalizable to other
studies.
The propensity scores were generated for the
three dermatologic disease arms versus the
control group, and certain people were
selected from the randomly created control
group using Mahalanobis matching [11]. All
variables, except for the exposure variable, were
included in the propensity score calculation. In
order to look for a balanced propensity score set,
we compared the covariates individually with
effect sizes and with a global test designed by
Hansen and Bowers [11, 12]. Continuous data
were reported as mean (standard deviation) and
categorical data were reported as n (%). Analyses
were performed in SAS 9.4 (SAS Institute, Cary,
NC, USA) and R [12].
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Participants
The sample sizes for the disease and control
groups were arrived at separately. For the
dermatologic disease group, we began with
people having either outpatient or inpatient
visits with ages inclusive between 30 and
64 years (n = 21,801,147). After excluding
patients that lacked diagnosis criteria,
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sufficient wash-out period, at least 1 year of
follow-up, and at least one outpatient record,
there were 4263 remaining patients (Fig. 1). For
the control group, we began with a simple
random sample of 20,000 people from the 2006
database. After excluding those of age less than
30 years or greater than 64 years, with less than
12 months of continuous enrollment, or with a
diagnosis of the dermatologic diseases
investigated, there were 14,162 patients.
Following the propensity score matching with
the combined dermatologic disease group, the
control sample size was 4263 patients. Our
sample consisted of n = 8526 people, matched
1:1 between the dermatologic diseases and
control groups.
Descriptive Data and Outcome Data
Our sample was comprised of people between
the ages of 30–64 years old with an average age
of 49.1 years [standard deviation (SD) 9.0].
Women comprised 67% of our total sample,
and 13% of the population had either type I or
type II diabetes. The sample had an average of
15.7 days of outpatient visits (SD 15.1), 0.3 days
of inpatient visits (SD 1.5), and 0.08
hospitalizations (SD 0.34) per year. The
average number of comorbidities was 0.28 (SD
0.57) and the average score of the modified
Charlson Comorbidity index was 0.34 (SD 0.8).
For health-related expenses, there were an
average US$8508 of total costs (SD 16,069),
Fig. 1 Flow diagram to identify exposure groups
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$1049 of inpatient costs (SD 6756), $3925 of
outpatient costs (SD 8735), and $1987 of
medication costs (SD 3927). For patients
diagnosed with AD, psoriasis, or rosacea, an
average of 3 dermatologic medications (SD 3)
were filled, resulting in an average annual cost
of $840 (SD 3261). All covariates, except the
number of inpatient and number of outpatient
days, had statistically significant differences
between the groups (Table 1).
The propensity score matching reduced the
Hansen and Bowers global test for balance
between treatment and control populations
from a Chi-square value of 1155 (p\0.0001)
to 12.4 (p = 0.0528).
Logistic Regression Model
We considered first an effects modification
model, and found that the overall test for
the variable was insignificant (F = 3.5118,
p = 0.3912), and we reported only the main
effects model. The model was highly predictive
of the outcome with an AUC value of 0.7935.
None of the three dermatologic disease groups
had statistically significant increased odds of
experiencing a CVD event at one year compared
to the control group, after controlling for all
other covariates (Table 2). In univariate
analysis, the unadjusted odds of cardiovascular
disease was higher in patients with psoriasis.
DISCUSSION
Systemic inflammation is a risk factor for
cardiovascular disease as inflammation
accelerates atherosclerosis [13–15].
Rheumatoid arthritis, psoriasis and other
diseases associated with chronic systemic
inflammation have been associated with
increased risk of CVD [16–23]. Our study
assessed whether three inflammatory
dermatologic conditions: psoriasis, AD, and
rosacea contribute to an independent risk of
cardiovascular at 1 year following diagnosis.
While psoriasis is associated with an
increased risk for cardiovascular outcomes, in
this study we did not detect independent
increased risk at 1-year follow-up after
adjusting for confounders. Prior studies have
shown patients with psoriasis and CVD share
many risk factors and the heterogeneity of
existing studies makes it difficult to determine
if psoriasis is truly an independent risk factor for
CVD [1]. Association of a disease with
confounders does not establish any association
with the corresponding disease itself. In our
study, patients with psoriasis had an increased
risk of developing CVD 1 year after diagnosis
before accounting for comorbidities, but this
difference vanished after accounting for
comorbidities. In our study, limited follow-up
of 1 year may also play a role in not identifying
psoriasis as an independent risk factor for CVD.
The risk between other inflammatory skin
conditions (AD and rosacea) has received only
limited evaluation.
We found that patients with AD did not have
statistically significant independent increased
odds of being diagnosed with CVD compared to
our propensity-matched control population at
1 year following diagnosis. Silverberg et al.
found that patients with atopic dermatitis are
more likely to have comorbid (high cholesterol,
hypertension, and diabetes) and environmental
habits (increased smoking and drinking with
decreased activity) that would pre-dispose AD
patients to developing CVD [7]; however, AD
does not appear to be a significant independent
risk factor. Our findings do contrast with the
findings from a Taiwanese retrospective
population-based study, which found patients
with AD having an elevated risk for ischemic
stroke (hazards ratio of 1.33) [8], while patients
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identified with severe AD had a more
pronounced risk of developing ischemic stroke
(hazards ratio of 1.7) over a follow-up period
of 1–4 years compared to their
comorbidity-matched counterparts. We
suspect that the longer follow-up period in
their study may explain the potential
discrepancy with our findings.
In our study, patients with rosacea were not
statistically more likely to have comorbidities or
an independent risk for cardiovascular disease.
This corroborates recent findings of Thyssen
et al. which also found patients with rosacea
were not more likely to have an independent
risk of CVD or an increase in CVD risk factors
(high cholesterol, LDL, and CRP) and
environmental habits (increased smoking and
drinking) [24]. A Taiwanese study did find that
rosacea was significantly associated with CV
comorbidities including dyslipidemia,
hypertension, and coronary artery disease,
although it lacked adjustment for important
CV risk factors such as smoking and alcohol
abuse [25].
Limitations
The large sample size gave our study power to find
even small clinical effect size. There were several
prominent potential confounders for which the
database does not collect data, including obesity
andsmokinganddrinkinghistory.Consequently,
we expect a degree of residual confounding that
may bias our estimate upward from the null. The
washout period can potentially select a
population with lower severity because it looks
for new treatment patients, but this may be
balanced by the fact that they are at least being
treated by prescription medications. The study
had a short follow-up period of 1 year, but there
was a cross-section of many patient ages. With
younger patients, 1 year may be insufficent to
detect an increased risk of CVD. We used a large
commercial claims database that is applicable to a
Table 2 Odds ratios of cardiovascular disease events
Crude odds ratio (95% CI) Adjusted odds ratio (95% CI) p valuea
Disease group
Rosacea 0.833 (0.691–1.004) 0.894 (0.732–1.091) 0.2713
Atopic dermatitis 0.893 (0.664–1.202) 1.032 (0.744–1.432) 0.8489
Psoriasis 1.223 (1.015–1.475) 1.087 (0.887–1.332) 0.4210
Control
Gender (male versus female) 2.330 (2.014–2.695) 2.172 (1.853–2.547) \0.0001
Age 1.104 (1.093–1.116) 1.092 (1.080–1.105) \0.0001
Diabetes 3.698 (3.133–4.365) 2.103 (1.644–2.464) \0.0001
Number of outpatient days 1.026 (1.022–1.030) 1.016 (1.011–1.022) \0.0001
Number of inpatient days 1.273 (1.224–1.325) 1.137 (1.085–1.192) \0.0001
Modiﬁed Charlson comorbidity index 1.593 (1.487–1.708) 1.074 (0.982–1.175) 0.1174
Total expenses 1.000 (1.000–1.000) 1.000 (1.000–1.000) 0.0006
CI conﬁdence interval
a For multivariate odds ratio
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large proportion of the population. Because this
claims database did not include Medicaid
patients, the magnitude of effect may not be
generalizable for indigent populations. Insurance
claims data do not provide information on
systemic inflammatory burden beyond the
diagnosis. Consequently, we have no way of
measuring the systemic inflammation burden of
skin disease.
CONCLUSIONS
Among patients diagnosed with one of three
common inflammatory dermatologic
conditions— psoriasis, AD, and rosacea—we
did not detect an independent increased risk
of CVD 1 year following diagnosis when
compared with a random sample of
propensity-matched patients with no evidence
of these three diseases. Before accounting for
covariates, patients with psoriasis appeared to
be at an increased risk for CVD 1 year following
diagnosis, but this was not significant after
adjusting for confounders. Physicians should
be aware of the higher rates of covariates in
patients with psoriasis which can predispose to
an increased risk of CVD.
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